化学
赫拉
体内
苯并咪唑
组蛋白脱乙酰基酶
顺铂
细胞培养
HDAC8型
药理学
癌症
HDAC1型
癌细胞
体外
组蛋白脱乙酰酶抑制剂
癌症研究
IC50型
细胞
作用机理
生物化学
结构-活动关系
生物活性
细胞生长
癌细胞系
酶抑制剂
激酶
乙酰化
作者
Junjie Chen,Weixu Wang,Xijin Qi,Naziyila Shayilan,Zhang Weiyi,Cheng Ma
标识
DOI:10.1021/acs.jmedchem.6c01456
摘要
The dual inhibition of phosphatidylinositol 3-kinase (PI3K) and histone deacetylase 8 (HDAC8) has emerged as a promising strategy for cervical cancer (CC) therapy. We synthesized 34 novel benzimidazole derivatives and evaluated their anti-CC cell line proliferation. The compound 50 exhibited equivalent antiproliferative effect to cisplatin (Pt) in CC cell lines SiHa, Ca Ski, and HeLa, especially in HeLa cells with an IC50 value at 1.42 ± 0.50 μM (Pt 1.70 ± 0.28 μM). Further assessment in the HeLa cell xenograft mouse model, the intraperitoneal medium- (30 mg/kg) and high-dose group (60 mg/kg) and and intragastric high-dose group (100 mg/kg) exhibited antitumor efficacy no less than that of Pt (i.p. 5 mg/kg) but much more safe during the experiment period. Mechanism studies demonstrated that 50 could inhibit the PI3K/Akt pathway and HDAC8 expression and function. These findings prove that the PI3K/HDAC8 dual inhibition may be an efficient way in cervical cancer treatment and compound 50 deserved for further development.
科研通智能强力驱动
Strongly Powered by AbleSci AI